ValiRx PLC - Final Results & Notice of AGM
ValiRx PLC
("ValiRx" or the "Company")
Final Results & Notice of AGM
Highlights
Operational Highlights:
· Completion of strategic review focussed on three core priorities;
1) Improved operational efficiency with administrative costs cut by
2) Enhanced commercial rigour in selecting evaluation programmes and licensing for new SPVs exemplified termination of Imperial Evaluation agreement and, post period, termination of StingRay and Dundee Evaluations together with signing of new evaluation agreements with Altus Healthcare and, post period, McGill University.
3) Maximising value from Group assets exemplified by the 3K Accelerator programme and PredictRx deals with Dominion Biotech together with expansion and development of Inaphaea Biolabs PDC Biobank.
· Termination of TheoremRx agreement and formation of Blue Ribbon Bio to develop Val 201.
· Successful out license of Val 401 to Ambrose Healthcare in exchange for equity.
· Strategic shift for Inaphaea BioLabs towards supporting ValiRx's own internal pipeline and the Group's new subsidiaries.
· Continued build of the capability partnerships with Cellomatics Biosciences and TwinEdge Bioscience who bring an exciting AI capability for biomarker discovery and in-silico clinical trials.
Financial Highlights:
· Total comprehensive loss for the year ended
· Research and development costs were
· Administrative expenses were
· Cash at the bank at
· Since the year end, further measures to reduce the annual cash burn include a combination of voluntary salary reductions, termination of the Advisory Board agreement with
Material uncertainty relating to going concern
The Auditors have drawn attention to the policy on Going Concern within note 2 to the financial statements, which indicates that the accounts have been prepared on the going concern basis. The Board has referred to the fact that the Group and Parent Company are reliant on future fund raisings to continue their activities as budgeted. Should future fund raisings be unsuccessful, this may cast significant doubt on the Group and parent Company's ability to continue as a going concern. The Auditors opinion is not modified in respect of this matter. The full Auditor's report is contained in the Company's Annual Report.
Notice of AGM
The Company's Annual General Meeting ("AGM") will be held at
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 as it forms part of
*** ENDS ***
Engage with the ValiRx management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor hub here: https://valirx.com/s/cc8ef3
For more information, please contact:
|
Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub |
https://valirx.com/link/eWdBAr
|
|
ValiRx plc
Dr
|
Tel: +44 115 784 0025 |
|
Cairn Financial Advisers LLP (Nominated Adviser)
|
Tel: +44 (0) 20 7213 0880 |
|
Shard Capital Partners LLP (Sole Broker)
|
Tel: +44 (0) 20 7186 9000 |
|
V Formation (Public Relations)
|
+44 (0) 115 787 0206
|
Subscribe to our news alert service: https://valirx.com/s/f298d1
Notes for Editors
About ValiRx
ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.
ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.
Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.
ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.
Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.
ValiRx listed on the AIM Market of the London Stock Exchange in
For further information, visit: www.valirx.com
Chairman and Chief Executives Report for the year ended
2025 has been a year of significant and purposeful evolution for ValiRx. Building on the strategic foundations laid during the second half of 2024, the Group has continued to restructure, focus, and advance both its commercial activities and its drug development pipeline. The progress achieved across all areas of the business during this period is a testament to the commitment and expertise of our lean, highly motivated team, and we are proud to report a year of meaningful milestones despite operating in one of the most challenging macro-economic environments in recent memory for early-stage life science companies.
Strategic Review: Completing the Transformation:
The comprehensive strategic and operational review initiated in Q4 2024 was completed during the first quarter of 2025. The review focused on three core priorities: improving operational efficiency and reducing cash burn; defining a clear and commercially rigorous approach to asset evaluation and in-licensing of the highest quality, later stage assets; and maximising the value of the Group's key scientific asset, Inaphaea BioLabs Patient-Derived Cell ("PDC") biobank together with its associated data sets as a critical internal resource for the Group's own programmes, partnering asset, and as a commercial revenue generator.
These priorities drove key structural decisions. The Inaphaea business model was deliberately re-oriented away from a dependence on third-party service revenues, which proved longer to convert in a subdued funding environment, towards a model in which Inaphaea's capabilities are deployed first and foremost to advance ValiRx's own internal pipeline, while also pursuing carefully selected out-licensing and commercial partnerships. This shift represents a more sustainable and strategically coherent use of Inaphaea's translational capabilities and its unique PDC biobank.
The restructuring saw the loss of three roles; Head of Operations & IT; Pre-clinical Project Manager and Head of Strategic Commercial Development, with responsibilities redistributed across the core team, supplemented by a new technician hired to support laboratory Inaphaea operations. The Board was streamlined, with Dr
The Group made meaningful progress in managing its cost base and has taken active steps to position itself for improved financial performance by broadening its commercial and academic ties. R&D tax credits of
The Group continues to seek and prosecute high value non-dilutive
Inaphaea BioLabs: A Pivotal Strategic Shift:
Inaphaea BioLabs remains the R&D engine of the Group and over the course of 2025, the nature of its role has evolved materially. The company continues to explore commercial revenue opportunities from out-licensing of its PDC models, but its primary strategic services focus has been redirected towards supporting ValiRx's own internal pipeline and the Group's new subsidiaries. This is a deliberate and well-considered change of direction given the macro-political environment which created significant uncertainty throughout the year, with global biotech and pharmaceutical funding remaining constrained. Grant opportunities from
Inaphaea's PDC biobank and associated data are key to its New Approach Methodology capabilities, which, together with a growing network of specialist partners represent a genuinely differentiated scientific asset; deploying that asset in service of the Group's own drug development programmes maximises both scientific output and long-term value creation.
Capabilities and Partnerships - Building an end-to-end development platform:
A defining feature of ValiRx's evolved strategy is its emphasis on capability building through partnerships, rather than seeking to maintain all expertise in-house. 2025 has seen the Group establish a genuinely differentiated and complementary network of scientific and commercial partners that significantly amplifies the capabilities available to support both internal programmes and PDC sales.
These include evaluation and co-marketing agreements with ScreenIn3D, Cellomatics Biosciences Ltd, and Dominion Biotech Ltd, as well as collaborations with VoxCell BioInnovation and TwinEdge Bioscience. These partnerships have multiple dimensions: they provide Inaphaea with referrals and access to a wider customer base; they give access to advanced testing capabilities for both internal and commercial programmes at low or no cost relative to outsourcing; and they create partnered development opportunities that can generate shared IP and future revenues.
Cellomatics Biosciences Ltd have six Colorectal Cancer PDC models in house for evaluation ahead of a potential roll-out to their own customer base, which would trigger a commercial use license and extending the evaluation post period to include co-culture with immune cells for in-vitro immunotherapy evaluation. This work will directly benefit our Cytolytix programme, highlighting our synergistic approach to partnering and capability building. Dominion signed a co-marketing agreement for PDC models as well as an agreement to co-develop repurposed assets identified through our 3k screening programme. The PredictRx™ personalised cancer therapy selection approach was also licensed to Dominion with regulatory and market planning initiated in Q4 2025.
Inaphaea continues to enhance and characterise its PDC biobank with establishment of new quality control protocols, data packets and prospective collection agreements with Nottingham Health Trust and, post period, the Christie NHS Foundation Trust. The combined bank of over 5,000 vials underpins the value of the biobank as a major asset for the Group, and expanding its quality, breadth and characterisation will be a key commercial priority going forward.
TwinEdge Bioscience - Digitising the PDC Platform:
One of the most exciting developments of 2025 has been the collaboration agreement with TwinEdge Bioscience, a Swiss innovator in digital twin technology for drug development. Under this agreement, TwinEdge is combining its proprietary methodology with drug response datasets obtained from Inaphaea's PDCs to create patient-derived avatars - digitally actionable representations of patient tumours that can be used for in-silico drug assessment. The initial phase of the collaboration, focused on four ovarian cancer PDC models, has been successfully completed and the data presented, post period, at the American Association of Cancer Research annual conference. The next phase will expand digital avatars across Inaphaea's remaining 63 ovarian PDC models with available RNA-sequence data. This partnership represents a material expansion of the Group's capabilities into digital drug discovery and positions our biobank data assets for use
A New Direction - TheoremRx and Val201:
ValiRx terminated the Letter of Intent with TheoremRx after they elected not to proceed with an agreed amendment to return the territory of
VAL201 was deemed to still have strong clinical relevance within the treatment pathway for prostate cancer under the new, stricter evaluation criteria, including its potential in addressing resistance to hormone therapies. Development work originally planned with TheoremRx will now be carried out through Blue Ribbon Bio Limited ("Blue Ribbon"), a new wholly owned subsidiary incorporated to house ValiRx's current and future prostate cancer-associated assets. Blue Ribbon will take on the existing intellectual property for VAL201, exclusively licensed from Cancer Research Horizons in 2010 with subsequent patents filed with ValiRx inventors in 2013 offering protection to 2033. Additional patent extension of up to 5 years following approval of a human or veterinary drug product may be obtained through a Patent Term Extension to the United States Patent and Trademark Office.
Modified VAL201 2.0 peptides were designed in house and received post period for testing at Inaphaea with a targeted series of pre-clinical tests designed to demonstrate improved efficacy and position the asset for licensing discussions. Options to fund Blue Ribbon independently of ValiRx are being actively explored, which would enable this important programme to be advanced without diluting ValiRx shareholders. We have taken a prudent approach to the valuation of this asset given the additional time required to validate the new constructs and have therefore written down the valuation to 60% of that included in the 2024 annual report.
Val401: A Successful Out-License:
Ambrose Healthcare Ltd exercised its option on VAL401, completing the out-licensing of this asset under pre-agreed terms. As part of the agreement, ValiRx received 576,000 ordinary shares in Ambrose Healthcare, equivalent to approximately 4.9% of issued Ambrose equity, with staged clinical and commercial milestone payments to Valiseek totalling up to
Cytolytix: Important Scientific Progress and New IP:
Cytolytix Limited, our majority-owned subsidiary focused on the development of CLX001, has made important scientific and commercial progress during 2025, and the pipeline of IP has been considerably strengthened with notice of allowance, and subsequent allowance post period, for the European Patent application on the original nanoparticle formulation. Claims for the original peptide patent were also confirmed as allowable, with accelerated examination requested. These are important de-risking milestones that provide a strengthened and more defensible IP foundation for CLX001 as it advances through pre-clinical development.
A key scientific priority for CLX001 in 2025 has been the identification and selection of a lead formulation for clinical development. Four formats are under evaluation: the original format developed by King's College London; an in-house lipid-based formulation; the Altus SmartCelle™ formulation; and a novel virus-based format developed in collaboration with Omios Biologics. The second-generation lipid delivery platform has been fully developed and evaluated in-house as well as in ScreenIn3D's UpScale3D lab-on-a-chip platform, incorporating Inaphaea's Triple Negative Breast Cancer PDC models and with BioReperia's zebrafish models. Preliminary data obtained post period support the potential to activate the host immune system and new, in-house patents filed.
Evaluation Pipeline - Quality over Quantity:
ValiRx's approach to evaluation agreements was materially refined during 2025. The Group now applies a stringent set of commercial and technical criteria to all evaluation decisions, with a focus on shorter, more nimble engagements over three to six months where Inaphaea can add significant and demonstrable value through its PDC biobank or pre-clinical capabilities. Importantly, under the new hybrid evaluation model, if an evaluated asset is returned but subsequently licensed externally, ValiRx would be compensated for added scientific and commercial value even if it does not ultimately in-license the asset. This model has been well received by academic and commercial partners.
Imperial College:
The Imperial College evaluation was concluded on
Dundee University:
The evaluation agreement with the University of Dundee was extended for a further year to
StingRay Bio:
A new-format agreement with StingRay Bio was signed in 2025. In-silico lead optimisation and in vitro experiments were performed on lead compounds identified during the first evaluation over a period of up to 12 months, with results jointly owned by ValiRx and StingRay. ValiRx holds an option to license the technology into a jointly-owned Special Purpose Vehicle, with its ownership increasing to 75% on completion of IND-enabling studies. Post period, ValiRx terminated the evaluation based on the stage of the asset and likely investment required to move to a drug candidate. Under the terms of the new arrangement, if StingRay secures alternative investment within 12 months of completion, ValiRx is entitled to a cash return of 1.5x its total investment of approximately
Altus Healthcare (CB2 Agonist / SmartCelle™):
An evaluation and option agreement with Altus Healthcare, was signed in
Further Evaluation Projects:
Active discussions for two further evaluation programmes under the new-format agreement, were underway during 2025 with a new evaluation and material transfer agreement being signed with McGill University, post period, in
3K Screen Programme: Unlocking Drug repositioning Opportunities:
One of the most exciting developments of the year was the progress of the 3K Screen programme, managed jointly by Inaphaea and Dominion Biotech Ltd under the agreement announced in
This is a uniquely capital-efficient approach to drug discovery: by focusing on approved drugs with established safety profiles, the time and cost required to advance a candidate to a clinical proof of concept are substantially reduced relative to traditional de novo drug development. We believe this programme has the potential to generate significant near-term value, and the Group is actively exploring partnering opportunities for the assets.
Outlook:
The macro-environment for early-stage life sciences remains challenging, and we do not underestimate the difficulty of operating in this context. However, the Group has never been better positioned scientifically, strategically, or in terms of the quality of its partnerships and pipeline. The combination of Inaphaea's unique PDC biobank, its growing New Approach Methodology capabilities, the TwinEdge digital twin platform, and the Group's expanding portfolio of drug development programmes creates a genuinely compelling and differentiated proposition in the oncology space.
· Completion of lead formulation selection for CLX001, progression to cGMP manufacture and IND-enabling studies, supported by results from ScreenIn3D and VoxCell evaluations.
· Progression of Blue-Ribbon Bio's VAL201 2.0 pre-clinical programme including IP filing, exploration of independent financing options and focused pre-clinical validation.
· Advancing the 3K Screen top 10 assets through full dose-response profiling, TwinEdge digital twin analysis, and commercial discussions with potential partners.
· Building the evaluation pipeline with two new agreements targeted under the new hybrid evaluation model.
· Completing the Dundee prosenescence mechanism of action studies towards a definitive in-licensing decision.
· Progressing the Altus CB2 / SmartCelle™ evaluation and determining next steps.
· Commercial launch of the PredictRx™ licence with Dominion
· Progressing
· Continuing to expand and digitise the PDC biobank through the TwinEdge collaboration.
· Completion of evaluation of second generation, orally available, RNA Helicase inhibitor from the Royal Institute for the Advancement of Learning/McGill University, a Canadian based University, and the Institute for Research in Immunology and Cancer - Commercialization of Research, a Canadian non-profit organisation four months ahead of schedule and exercised its option to negotiate definitive agreements for an exclusive licence of intellectual property rights to be granted to a newly incorporated Canadian entity.
· Incorporation of ValiRx Animal Health Limited to develop and commercialise ValiRx's existing and future oncology assets in the veterinary market.
Financial overview
Our financial results show the total comprehensive loss for the year ended
Research and development costs were
Administrative expenses were
Cash at the bank at
Since the year end, we have taken measures to reduce the annual cash burn through a combination of voluntary salary reductions, termination of the Advisory Board agreement with
None of this would be possible without the dedication and diligence from our staff and board and we would like to extend our gratitude for the hard work as we strive to build on the progress made.
We look forward to updating shareholders on our continued progress throughout 2026.
|
|
Dr M Eccleston |
|
Chairman |
Chief Executive Officer |
|
Date: |
Date: |
Consolidated Statement of Profit or Loss and Other Comprehensive Income for the year ended
|
|
2025 |
2024 |
|
|
£ |
£ |
|
CONTINUING OPERATIONS |
|
|
|
TURNOVER |
31,372 |
49,775 |
|
Cost of sales |
(37,622) |
(62,869) |
|
GROSS PROFIT |
(6,250) |
(13,094) |
|
Other operating income |
- |
30,000 |
|
Research and developments |
(229,378) |
(245,163) |
|
Impairment of goodwill |
(598,022) |
- |
|
Administrative expenses |
(1,586,837) |
(1,913,414) |
|
|
|
|
|
OPERATING LOSS |
(2,420,487) |
(2,141,671) |
|
Finance costs |
(3,328) |
(1,279) |
|
Finance income |
8,476 |
12,495 |
|
LOSS BEFORE INCOME TAX |
(2,415,339) |
(2,130,455) |
|
Income tax credit |
126,355 |
127,696 |
|
LOSS AFTER INCOME TAX |
(2,288,984) |
(2,002,759) |
|
Non-controlling interest |
56,824 |
87,066 |
|
TOTAL COMPREHENSIVE LOSS FOR THE YEAR |
(2,232,160) |
(1,915,693) |
|
|
|
|
|
LOSS PER SHARE - BASIC AND DILUTED |
(0.54p) |
(1.45p) |
Consolidated Statement of Financial Position for the year ended
|
|
|
|
|
|
|
|
|
2025 |
2024 |
|
||
|
|
£ |
£ |
|
||
|
ASSETS |
|
|
|
||
|
NON-CURRENT ASSETS |
|
|
|
||
|
Goodwill |
1,004,500 |
1,602,522 |
|
||
|
Intangible assets |
381,489 |
530,937 |
|
||
|
Property, plant and equipment |
129,671 |
201,662 |
|
||
|
Right-of-use assets |
- |
- |
|
||
|
Investments |
30,000 |
30,000 |
|
||
|
|
1,545,660 |
2,365,121 |
|
||
|
|
|
|
|
||
|
CURRENT ASSETS |
|
|
|
||
|
Inventory |
69,002 |
69,002 |
|
||
|
Trade and other receivables |
99,698 |
134,592 |
|
||
|
Tax receivable |
125,653 |
137,405 |
|
||
|
Cash and cash equivalents |
791,612 |
1,555,986 |
|
||
|
|
1,085,965 |
1,896,985 |
|
||
|
|
|
|
|
||
|
TOTAL ASSETS |
2,631,625 |
4,262,106 |
|
||
|
|
|
|
|
||
|
EQUITY |
|
|
|
||
|
SHAREHOLDERS' EQUITY |
|
|
|
||
|
Called up share capital |
10,347,667 |
9,979,295 |
|
||
|
Share premium |
30,988,965 |
30,613,044 |
|
||
|
Merger reserve |
637,500 |
637,500 |
|
||
|
Reverse acquisition reserve |
602,413 |
602,413 |
|
||
|
Share option reserve |
886,036 |
976,920 |
|
||
|
Retained earnings |
(40,607,546) |
(38,491,790) |
|
||
|
|
2,855,035 |
4,317,382 |
|
||
|
Non-controlling interests |
(458,513) |
(401,689) |
|
||
|
TOTAL EQUITY |
2,396,522 |
3,915,693 |
|
||
|
|
|
|
|
||
|
LIABILITIES |
|
|
|
||
|
NON-CURRENT LIABILITIES |
|
|
|
||
|
Borrowings |
- |
1,390 |
|
||
|
|
- |
1,390 |
|
||
|
|
|
|
|
||
|
CURRENT LIABILITIES |
|
|
|
||
|
Trade and other payables |
233,708 |
334,551 |
|
||
|
Borrowings |
1,395 |
10,472 |
|
||
|
|
235,103 |
345,023 |
|
||
|
|
|
|
|
||
|
TOTAL LIABILITIES |
235,103 |
346,413 |
|
||
|
|
|
|
|
||
|
TOTAL EQUITY AND LIABILITIES |
2,631,625 |
4,262,106 |
|
||
Consolidated Statement of Changes in Equity for the year ended
|
|
Share capital |
Share premium |
Merger reserve |
Reverse acquisition reserve |
Share-based payment reserve |
Non-controlling interest |
Retained earnings |
Total |
|
|
£ |
£ |
£ |
£ |
£ |
£ |
£ |
£ |
|
|
|
|
|
|
|
|
|
|
|
Balance at |
9,707,266 |
27,870,548 |
637,500 |
602,413 |
1,082,163 |
(314,623) |
(36,681,340) |
2,903,927 |
|
Changes in equity |
|
|
|
|
|
|
|
|
|
Loss for the year |
- |
- |
- |
- |
- |
(87,066) |
(1,915,693) |
(2,002,759) |
|
Issue of shares |
272,029 |
3,102,715 |
- |
- |
- |
- |
- |
3,374,744 |
|
Cost of shares issued |
- |
(360,219) |
- |
- |
- |
- |
- |
(360,219) |
|
Lapse of share options and warrants |
- |
- |
- |
- |
(105,243) |
- |
105,243 |
- |
|
Balance at |
9,979,295 |
30,613,044 |
637,500 |
602,413 |
976,920 |
(401,689) |
(38,491,790) |
3,915,693 |
|
Changes in equity |
|
|
|
|
|
|
|
|
|
Loss for the year |
- |
- |
- |
- |
- |
(56,824) |
(2,232,160) |
(2,288,984) |
|
Issue of shares |
368,372 |
552,559 |
- |
- |
- |
- |
- |
920,931 |
|
Cost of shares issued |
- |
(151,118) |
- |
- |
- |
- |
- |
(151,118) |
|
Lapse of share options and warrants |
- |
- |
- |
- |
(116,404) |
- |
116,404 |
- |
|
Movement in year |
- |
(25,520) |
- |
- |
25,520 |
- |
- |
- |
|
Balance at |
10,347,667 |
30,988,965 |
637,500 |
602,413 |
886,036 |
(458,513) |
(40,607,546) |
2,396,522 |
Consolidated Statement of Cash Flows for the year ended
|
|
|
2025 |
2024 |
|
|
|
Notes |
£ |
£ |
|
|
Cash flows from operations |
|
|
|
|
|
Cash outflow from operations |
1 |
(1,653,395) |
(1,761,539) |
|
|
Interest paid |
|
(3,328) |
(1,279) |
|
|
Interest received |
|
8,476 |
12,495 |
|
|
Tax credit received |
|
138,107 |
165,464 |
|
|
Net cash outflow from operating activities |
|
(1,510,140) |
(1,584,859) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from investing activities |
|
|
|
|
|
Purchase of intangible fixed assets |
|
|
- |
|
|
Purchase of property, plant and equipment |
|
(13,580) |
(38,156) |
|
|
Net cash outflow from investing activities |
|
(13,580) |
(38,156) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities |
|
|
|
|
|
Bank loan repayment |
|
(10,467) |
(10,208) |
|
|
Share issue |
|
920,931 |
3,374,744 |
|
|
Costs of shares issued |
|
(151,118) |
(360,219) |
|
|
Net cash inflow from financing activities |
|
759,346 |
3,004,317 |
|
|
|
|
|
|
|
|
Increase/(decrease) in cash and cash equivalents |
|
(764,374) |
1,381,302 |
|
|
|
|
|
|
|
|
Cash and cash equivalents at beginning of year |
2 |
1,555,986 |
174,684 |
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of year |
2 |
791,612 |
1,555,986 |
|
Notes to the Consolidated Statement of Cash Flows for the year ended
|
1. |
RECONCILIATION OF OPERATING LOSS TO CASH GENERATED FROM OPERATIONS |
|
|
|
2025 |
|
2024 |
|
|
|
£ |
|
£ |
|
|
|
|
|
|
|
Operating loss |
|
(2,420,487) |
|
(2,141,671) |
|
Amortisation and impairment of intangible assets |
|
149,448 |
|
187,877 |
|
Impairment of goodwill |
|
598,022 |
|
- |
|
Depreciation of property, plant and equipment |
|
85,571 |
|
79,119 |
|
Decrease in trade and other receivables |
|
34,894 |
|
13,026 |
|
Increase/(decrease) in trade and other payables |
|
(100,843) |
|
130,110 |
|
Acquisition of investment for non-cash consideration |
|
- |
|
(30,000) |
|
Net cash outflow from operations |
|
(1,653,395) |
|
(1,761,539) |
2. CASH AND CASH EQUIVALENTS
The amounts disclosed on the Statement of Cash Flows in respect of cash and cash equivalents are in respect of these Statement of Financial Position amounts:
|
|
|
|
|
|
|
|
|
£ |
|
£ |
|
Cash and cash equivalents |
|
791,612 |
|
1,555,986 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
£ |
|
£ |
|
Cash and cash equivalents |
|
1,555,986 |
|
174,684 |
Notes to the Consolidated Financial Statements for the year ended
1. STATUTORY INFORMATION
ValiRx Plc is a public company limited by shares, incorporated in the
The registered number of the Company is 03916791.
The principal activity of the Group is the development of oncology therapeutics and companion diagnostics.
The presentation currency of the financial statements is the Pound Sterling (£), rounded to the nearest
2. ACCOUNTING POLICIES
Basis of preparation
The Group's financial statements have been prepared in accordance with International Accounting Standards in conformity with the requirements of the Companies Act 2006 as they apply to the financial statements of the Group for the year ended
The Group financial statements have been prepared under the historical cost convention or fair value where appropriate.
Going concern
As part of their going concern review the Directors have followed the guidelines published by the Financial Reporting Council entitled "Guidance on the Going Concern Basis of Accounting and Reporting on Solvency Risks - Guidance for directors of companies that do not apply the
The current economic environment is challenging, and the Group has reported an operating loss for the year. These losses are expected to continue in the current accounting year to
The Directors have prepared detailed financial forecasts and cashflows looking beyond 12 months from the date of the approval of these financial statements. In developing these forecasts, the Directors have made assumptions based upon their view of the current and future economic conditions that are expected to prevail over the forecast period. The Directors estimate that the cash of
The Company carries out regular fund-raising exercises in order that it can provide the necessary working capital for the Group. Further funds may be required to finance the Group's work programme. The Board expects to continue to raise additional funding as and when required to cover the Group's
development, primarily from the issue of further shares.
In the event that additional financing is not secured when it is required, the Group would need to
consider:
• reducing and/or deferring discretionary spending on one or more research and development
programmes; and/or
• restructuring operations to change its overhead structure.
Basis of consolidation
The Group financial statements consolidate the financial statements of the Company and all its subsidiaries ("the Group"). Subsidiaries include all entities over which the Group has the power to govern financial and operating policies. The existence and effect of potential voting rights that are currently exercisable or convertible are considered when assessing whether the Group controls another entity. Subsidiaries are consolidated from the date on which control commences until the date that control ceases. Intra-group balances and any unrealised gains and losses on income or expenses arising from intra-group transactions, are eliminated in preparing the consolidated financial statements.
On
In
agreement. The company has a 55.5% holding in the issued share capital of ValiSeek.
In
3. LOSS PER SHARE
The loss and number of shares used in the calculation of loss per ordinary share are set out below:
|
|
|
2025 |
|
2024 |
|
|
|
£ |
|
£ |
|
|
|
|
|
|
|
Loss for the financial period |
|
(2,288,984) |
|
(2,002,759) |
|
Non-controlling interest |
|
56,824 |
|
87,066 |
|
|
|
|
|
|
|
Loss attributable to owners of Parent Company |
|
(2,232,160) |
|
(1,915,693) |
|
|
|
|
|
|
|
Basic: |
|
|
|
|
|
Weighted average number of shares |
|
413,521,875 |
|
131,774,347 |
|
Loss per share |
|
(0.54p) |
|
(1.45p) |
The loss and the weighted average number of shares used for calculating the diluted loss per share are identical to those for the basic loss per share. The outstanding share options and share warrants would have the effect of reducing the loss per share and would therefore not be dilutive under IAS 33 'Earnings per Share'.
4. REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF VALIRX PLC
Opinion
We have audited the financial statements of ValiRx Plc (the 'Parent Company') and its subsidiaries (the 'Group') for the year ended
In our opinion:
· the financial statements give a true and fair view of the state of the Group's and of the Parent Company's affairs as at
· the Group's financial statements have been prepared in accordance with
· the Parent Company financial statements have been properly prepared in accordance with
· the financial statements have been prepared in accordance with the requirements of the Companies Act 2006.
Basis for opinion
We conducted our audit in accordance with International Standards on Auditing (
Emphasis of Matter
We draw attention to the value of goodwill in the Consolidated Statement of Financial Position and the value of investments in the Company Statement of Financial Position. The value of investments represents the historic cost of acquisition of investments less provisions for impairment. The value of goodwill arises on consolidation and represents the excess between the value of the underlying subsidiary on acquisition and the cost of investment, less provisions for impairment.
Management's assessment of impairment includes a review of the net present value of future potential cashflows of the underlying assets. The basis of these valuations include a number of variables within the calculations that are subjective and based on professional judgements of expectations and estimates. This also includes the expected potential around the success of the future development and commercialisation of the Group's products, VAL 201 and VAL 401.
While we have assessed management's judgements and application of estimates in their calculations and consider these to be reasonable, as set out in the key audit risks below, there are several factors that could result in a material change in the valuation of the underlying investments which could result in an impairment of the investments and associated goodwill.
Our opinion is not modified in respect of this matter.
Material uncertainty relating to going concern
We draw your attention to the policy on Going Concern within note 2 to the financial statements, which indicates that the accounts have been prepared on the going concern basis. The Board has referred to the fact that the Group and Parent Company are reliant on future fund raisings to continue their activities as budgeted. Should future fund raisings be unsuccessful, this may cast significant doubt on the Group and parent Company's ability to continue as a going concern.
Our opinion is not modified in respect of this matter.
The full auditor report can be found in the Company's annual accounts for the year ended
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE